Ortho evra and Application site rash - a phase IV clinical study of FDA data

Summary:

Application site rash is reported as a side effect among people who take Ortho evra (ethinyl estradiol; norelgestromin), especially for people who are female, 20-29 old, have been taking the drug for < 1 month also take Zithromax, and have Depression.

The phase IV clinical study analyzes which people have Application site rash when taking Ortho evra. It is created by eHealthMe based on reports of 29,122 people who have side effects when taking Ortho evra from the FDA, and is updated regularly.

What is Ortho evra?

Ortho evra has active ingredients of ethinyl estradiol; norelgestromin. It is often used in birth control. eHealthMe is studying from 29,275 Ortho evra users. Check the latest studies of Ortho evra.

What is Application site rash?

Application site rash is found to be associated with 393 drugs and 629 conditions by eHealthMe. Check the latest studies of Application site rash.

On Aug, 08, 2026

29,122 people reported to have side effects when taking Ortho evra.
Among them, 53 people (0.18%) have Application site rash.

Could Ortho evra cause Application site rash?

Among these 53 people:

How long have people been on Ortho evra when they have Application site rash? *

What is the gender of people who have Application site rash when taking Ortho evra? *

female: 100 %
male: 0.0 %

What is the age of people who have Application site rash when taking Ortho evra? *

What are other drugs people take besides Ortho evra? *

What are other side effects people have besides Application site rash? *

Application Site Pruritus (application site severe itching of the skin): 11 people, 20.75%
Application Site Reaction: 7 people, 13.21%
Application Site Discoloration: 5 people, 9.43%
Application Site Pain: 5 people, 9.43%
Application Site Erosion: 5 people, 9.43%
Application Site Erythema (redness of the skin at application site): 4 people, 7.55%
Application Site Irritation: 3 people, 5.66%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 3 people, 5.66%
Vaginal Bleeding: 3 people, 5.66%
Nausea (feeling of having an urge to vomit): 2 people, 3.77%

What are the existing conditions these people have? *

Depression: 3 people, 5.66%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 2 people, 3.77%
Asthma: 2 people, 3.77%
Tooth Disorder (tooth disease): 1 person, 1.89%
Stress And Anxiety: 1 person, 1.89%
Sleep Disorder: 1 person, 1.89%
Sinus Disorder (disease of sinus): 1 person, 1.89%
Multiple Allergies (allergy to multiple agents): 1 person, 1.89%
Hypomenorrhea: 1 person, 1.89%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 1.89%

* Approximation only. Some reports may have incomplete information.

Do you take Ortho evra and have Application site rash?

- Check whether Application site rash is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ortho evra:

Ortho evra (29,275 reports)

Application site rash treatments and more:

Application site rash (13,861 reports)

How severe was Application site rash and when was it recovered:

Application site rash in Ortho evra

Expand to all the drugs that have ingredients of ethinyl estradiol; norelgestromin:

Application site rash and drugs with ingredients of ethinyl estradiol; norelgestromin (182 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ortho evra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site rash:

Application site rash (393 drugs)

Browse all the conditions that are associated with Application site rash:

Application site rash (629 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ethinyl estradiol; norelgestromin (the active ingredients of Ortho evra) and Ortho evra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.